Approval · Notice of Compliance 830 · 2002
DOM-DIVALPROEX: Notice of Compliance 830
Issued April 10, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 830
- Date
- April 10, 2002
- Company
- Dominion PharmacalMontreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New product and manufacturer name
- Therapeutic class
- Anticonvulsant
- Canadian reference product
- EPIVAL (Abbott Laboratories Co.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DOM-DIVALPROEX | 02245751 | Cancelled Post Market |
| DOM-DIVALPROEX | 02245752 | Cancelled Post Market |
| DOM-DIVALPROEX | 02245753 | Cancelled Post Market |
Medicinal ingredients
- DIVALPROEX SODIUM 125 MG per TAB
- DIVALPROEX SODIUM 250 MG per TAB
- DIVALPROEX SODIUM 500 MG per TAB